Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMothercare Regulatory News (MTC)

Share Price Information for Mothercare (MTC)

Share Price is delayed by 15 minutes
Get Live Data
1.00    0.015 (1.52%)
Bid:
0.755
Ask:
1.00
Spread: 0.245 (32.45%)
Market Cap: £5.64m
MTC Live PriceLast checked at - London Stock Exchange

Intraday Mothercare Share Chart

Trading Statement

10 May 2024 07:00

Trading Statement

Mothercare plc

Pre-close trading update

Mothercare plc ("Mothercare" or "the Company"), the leading specialist global brand for parents and young children, today issues a pre-close trading update for the 53 week period to 30 March 2024 (“FY24”). Comparatives are based on the 52 week period to 25 March 2023. This update is based upon draft figures pending finalisation of the year end audit.

Highlights

Unaudited net worldwide retail sales by franchise partners of £281 million for the year, representing a decline of 13%.Adjusted EBITDA for FY24 marginally above the £6.7 million achieved in the previous year and in line with market expectations.Net debt of £14.7 million at the year end.Pension scheme deficit remains at £35 million (March 2023: £35 million).

EBITDA before adjusting items, for the financial year to 30 March 2024, is now expected to be marginally above the £6.7 million achieved in the year to 25 March 2023, showing a continuing year on year improvement in the underlying profitability of the business.

Unaudited net worldwide retail sales by franchise partners were £281 million, compared to £323 million for the previous financial year. The year-on-year decline in retail sales of 13% reduces to 8% at constant currency exchange rates. Our Middle East markets (41% of our total retail sales) continued to be the most challenging, particularly in the latter part of the financial year. The UK and Indonesia operations were amongst the markets that increased retail sales year-on-year, with Indonesia growing to become our second largest market by retail sales behind the Kingdom of Saudi Arabia. As previously reported, in addition to the global economic uncertainties which are impacting our retail sales, in many of our territories our partners are still clearing inventory due to the suppressed demand during Covid-19.

We expect these factors will continue to impact the Group results in FY25, notwithstanding ongoing improvements in product and service, although our medium-term guidance is unchanged for the steady state operation in more normal circumstances. We continue to believe our continuing franchise operations remain capable of exceeding £10 million operating profit and maintain our focus on accelerating our growth in both existing and new markets.

Financing

At the year-end Mothercare had total cash of £5.0 million (March 2023: £7.1 million), against the £19.7 million (March 2023: £19.5 million) of the Group’s existing loan facility, which remained fully drawn across the year.

With interest rates remaining at an elevated level, the interest rate on the Group’s existing loan facility is currently approximately 19.2%, which coupled with the extended time to return to pre-pandemic retail sales levels, particularly in our Middle Eastern markets, highlighted above, means the Board’s current forecasts for continuing operations show the Group requires waivers to our covenant tests. We have therefore commenced refinancing discussions with our lender to vary, renegotiate or refinance this debt facility. Additionally, we are well advanced in looking at various financing alternatives (including equity and equity linked structures) to give us both additional flexibility and reduced cash financing costs. For the avoidance of doubt the Group does not require (and is not seeking through this refinancing) additional liquidity.

Clive Whiley, Chairman of Mothercare, commented:

“As highlighted in my last Chairman’s statement, it has been six years of hard work and transformative change for the Group and, on behalf of the Board, I would like to thank our colleagues across the business, alongside our pension trustees and all other stakeholders for their unstinting support during these difficult times. That support and the resilience we have built into the business throughout this journey, allows us to deal with the major challenges we have faced and Mothercare operations would not be in the profitable and cash generative position we are today without it.

Given the exogenous factors influencing some of the Company’s operating markets, our immediate priority remains to support our franchise partners, ultimately for the benefit of our own business, however we have also redoubled our efforts to restore critical mass and are focused upon monetising the Mothercare global brand IP. This remains an exciting prospect for our partners, our colleagues and all stakeholders.”

Investor and analyst enquiries to:Mothercare plc Email: investorrelations@mothercare.comClive Whiley, ChairmanAndrew Cook, Chief Financial Officer Deutsche Numis Tel: 020 7260 1000(NOMAD & Joint Corporate Broker) Luke BordewichHenry Slater

Cavendish Capital Markets Limited Tel: 020 7220 0500(Joint Corporate Broker) Carl Holmes

Media enquiries to:MHP Email: mothercare@mhpc.comRachel Farrington Tel: 07801 894577Tim Rowntree

Date   Source Headline
13th Sep 20237:19 amGNWBlock listing Interim Review
4th Jul 20239:43 amGNWHolding(s) in Company
9th Jun 20237:00 amGNWDirectorate change
4th May 20237:00 amGNWPre-close Trading Update
27th Mar 20238:06 amGNWDirector/PDMR Shareholding
13th Mar 20238:00 amGNWBlock listing Interim Review
2nd Mar 20234:35 pmRNSPrice Monitoring Extension
8th Feb 202310:45 amRNSDirector/PDMR Shareholding
3rd Feb 20234:40 pmRNSSecond Price Monitoring Extn
3rd Feb 20234:35 pmRNSPrice Monitoring Extension
3rd Jan 20239:00 amRNSDirector/PDMR Shareholding
23rd Dec 20227:00 amRNSFurther re: Appointment of Chief Executive Officer
15th Dec 20224:40 pmRNSSecond Price Monitoring Extn
15th Dec 20224:35 pmRNSPrice Monitoring Extension
24th Nov 20227:00 amRNSInterim results announcement
24th Nov 20227:00 amGNWAppointment of Chief Executive Officer
21st Nov 20224:36 pmRNSPrice Monitoring Extension
13th Oct 202212:38 pmGNWAGM Statement
16th Sep 20228:04 amGNWAnnual Report and Accounts and Notice of AGM
14th Sep 20221:31 pmGNWDirector/PDMR Shareholding
13th Sep 20224:40 pmRNSSecond Price Monitoring Extn
13th Sep 20224:35 pmRNSPrice Monitoring Extension
13th Sep 20224:12 pmGNWBlock listing Interim Review
13th Sep 20223:38 pmRNSFull Year Results 2022
16th May 20224:41 pmRNSSecond Price Monitoring Extn
16th May 20224:35 pmRNSPrice Monitoring Extension
4th May 20224:40 pmRNSSecond Price Monitoring Extn
4th May 20224:36 pmRNSPrice Monitoring Extension
11th Apr 20227:00 amGNWPre-close Trading Update
14th Mar 20229:12 amGNWBlock listing Interim Review
9th Mar 20227:00 amRNSStatement re Russia
24th Feb 20223:36 pmGNWHolding(s) in Company
24th Feb 202212:38 pmGNWHolding(s) in Company
4th Jan 20228:42 amGNWHolding(s) in Company
25th Nov 20217:00 amRNSInterim results announcement
27th Oct 202110:52 amGNWHolding(s) in Company
13th Sep 20218:15 amGNWBlock listing Interim Review
9th Sep 202111:49 amGNWAGM Statement and trading update
7th Sep 20217:10 amGNWHolding(s) in Company
10th Aug 202111:30 amGNWNotice of Annual General Meeting and Annual Report and Accounts
3rd Aug 20214:40 pmRNSSecond Price Monitoring Extn
3rd Aug 20214:35 pmRNSPrice Monitoring Extension
29th Jul 20217:00 amRNSFinal Results
5th Jul 20217:15 amGNWHolding(s) in Company
9th Jun 20214:41 pmRNSSecond Price Monitoring Extn
9th Jun 20214:36 pmRNSPrice Monitoring Extension
25th May 20217:00 amGNWPre-close Trading and Business Update
10th May 20219:00 amGNWStatement re timing of FY21 pre-close trading update
1st Apr 20213:57 pmGNWTotal voting rights
25th Mar 20214:41 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.